The price of Enhabit Inc (NYSE: EHAB) closed at $9.82 in the last session, up 1.34% from day before closing price of $9.69. In other words, the price has increased by $+0.13 from its previous closing price. On the day, 620812 shares were traded. EHAB stock price reached its highest trading level at $9.99 during the session, while it also had its lowest trading level at $9.59.
Elon Musk just Triggered a BOOM in These Stocks
Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"
Click Here to Download the FREE Report.
Sponsored
Ratios:
We take a closer look at EHAB’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.52 and its Current Ratio is at 1.52. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.86.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, SVB Securities on June 20, 2023, initiated with a Underperform rating and assigned the stock a target price of $10.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 26 when Bolton Jeffrey bought 2,000 shares for $11.61 per share. The transaction valued at 23,220 led to the insider holds 19,597 shares of the business.
SHAW L EDWARD JR bought 10,000 shares of EHAB for $119,800 on May 22. The Director now owns 38,989 shares after completing the transaction at $11.98 per share. On May 18, another insider, Langham Ronald Leroy JR, who serves as the EVP Clinical Excel. & Strategy of the company, bought 10,000 shares for $11.99 each. As a result, the insider paid 119,900 and bolstered with 44,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EHAB now has a Market Capitalization of 492.27M and an Enterprise Value of 1.08B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46 while its Price-to-Book (P/B) ratio in mrq is 0.73. Its current Enterprise Value per Revenue stands at 1.03 whereas that against EBITDA is -9.64.
Stock Price History:
Over the past 52 weeks, EHAB has reached a high of $16.64, while it has fallen to a 52-week low of $7.12. The 50-Day Moving Average of the stock is 9.60, while the 200-Day Moving Average is calculated to be 12.22.
Shares Statistics:
According to the various share statistics, EHAB traded on average about 708.90K shares per day over the past 3-months and 776.72k shares per day over the past 10 days. A total of 50.10M shares are outstanding, with a floating share count of 44.13M. Insiders hold about 11.92% of the company’s shares, while institutions hold 113.44% stake in the company. Shares short for EHAB as of Oct 30, 2023 were 4.78M with a Short Ratio of 4.78M, compared to 4.59M on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.54% and a Short% of Float of 13.04%.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.07 for the current quarter, with a high estimate of $0.17 and a low estimate of $0.01, while EPS last year was $0.32. The consensus estimate for the next quarter is $0.06, with high estimates of $0.1 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.35 and $0.16 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.23, with 7 analysts recommending between $0.37 and $0.06.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $260.26M. It ranges from a high estimate of $263.9M to a low estimate of $257.43M. As of the current estimate, Enhabit Inc’s year-ago sales were $275.1M, an estimated decrease of -5.40% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $264.28M, a decrease of -2.60% over than the figure of -$5.40% in the same quarter last year. There is a high estimate of $270M for the next quarter, whereas the lowest estimate is $260.41M.
A total of 7 analysts have provided revenue estimates for EHAB’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $1.04B, resulting in an average revenue estimate of $1.05B. In the same quarter a year ago, actual revenue was $1.08B, down -3.40% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.09B and the low estimate is $1.05B. The average revenue growth estimate for next year is up 2.50% from the average revenue estimate for this year.
